Carbon nanoparticles versus patent blue dye for detection of sentinel lymph node in patients with early breast cancer

被引:0
|
作者
Elsebaai, Mahmoud R. M. [1 ]
Shehab, Mohamed A. H. [1 ]
Hanafy, Dina M. [1 ]
Abd Al Moaty, Karim F. [1 ]
机构
[1] Ain Shams Univ, Fac Med, Gen Surg, 32 Mohamed Ibrahim, Cairo 11788, Egypt
来源
EGYPTIAN JOURNAL OF SURGERY | 2024年 / 43卷 / 02期
关键词
carbon nanoparticles; patent blue V dye; sentinel lymph nodes; QUALITY-OF-LIFE; BIOPSY; MULTICENTER; IDENTIFICATION; DISSECTION;
D O I
10.4103/ejs.ejs_311_23
中图分类号
R61 [外科手术学];
学科分类号
摘要
BackgroundSentinel lymph nodes biopsy (SLNB) has replaced axillary lymph node dissection (ALND) in a considerable percentage of patients with early-stage breast cancer which was a great advance in preventing many surgical complications and enhancing their health welfare. Although there are different sentinel lymph nodes (SLNs) tracers with different identification rates, there is no agreement about the idealistic method.AimThe study was designed to compare carbon nanoparticles and patent blue v dye regarding SLNs detection rate, number of SLNs, time of detection, metastatic SLNs, cost, and safety in patients with early breast cancer and clinically node-negative axilla.Patients and methodsA total of 40 patients with axillary lymph node-negative early-stage breast cancer patients were divided into two groups and subjected to carbon nanoparticles and patent blue V dye in group A and group B, respectively. Patients who were pregnant or lactating had node-positive axilla (N1-3) or metastatic breast cancer (M1) or had neoadjuvant chemotherapy were excluded.ResultsThe mean age was 48.3 +/- 9.5 and 47 +/- 8.9, while the mean BMI of 33.3 +/- 4.8 and 32.834 +/- 4.862, the SLN detection rates were 95% and 90% in groups A and B, respectively. A total of 128 sentinel lymph nodes (SLNs) were removed from patients in the two groups (65 with Carbon Nanoparticles and 63 with patent blue dye). The mean number of SLNs was 3.4 +/- 0.7 (range, 2-5) and 3.5 +/- 1.2 (range, 2-7), mean time of SLNs detection was 13.5 +/- 4.5 (range, 7-22) and 12.7 +/- 3.6 (range, 7-18 min) between group A and B, respectively.ConclusionThere is no significant difference between carbon nanoparticles and patent blue dye regarding axillary SLNs in early breast cancer regarding identification rate, number of SLNs, time of detection, metastatic SLNs, cost, and safety with slight preference to carbon nanoparticles regarding postoperative skin staining and Egyptian market availability.
引用
收藏
页码:485 / 492
页数:8
相关论文
共 50 条
  • [1] Sentinel Lymph Node Detection Using Carbon Nanoparticles in Patients with Early Breast Cancer
    Wu, Xiufeng
    Lin, Qingzhong
    Chen, Gang
    Lu, Jianping
    Zeng, Yi
    Chen, Xia
    Yan, Jun
    PLOS ONE, 2015, 10 (08):
  • [2] Use of Fluorescence Imaging in Combination with Patent Blue Dye versus Patent Blue Dye Alone in Sentinel Lymph Node Biopsy in Breast Cancer
    Tong, Meng
    Guo, Wenbin
    Gao, Wei
    JOURNAL OF BREAST CANCER, 2014, 17 (03) : 250 - 255
  • [3] A prospective randomized trial comparing patent blue and methylene blue for the detection of the sentinel lymph node in breast cancer patients
    Paulinelli, Regis Resende
    Freitas-Junior, Ruffo
    de Souza Rahal, Rosemar Macedo
    de Padua Oliveira, Luis Fernando
    Tavares Vilela, Maria Helena
    Reboucas Moreira, Marise Amaral
    Alves, Katyane Larissa
    Peleja, Marina Berquo
    Capel de Resende, Tatiane Coelho
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2017, 63 (02): : 118 - 123
  • [4] Sentinel lymph node detection with indocyanine green and patent blue dye in cervical cancer: A single-centre feasibility study
    Preston, Marta
    McBain, Rosemary
    Rajadevan, Niveditha
    Jones, Antonia
    Neesham, Deborah
    McNally, Orla
    AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2024, 64 (06): : 573 - 579
  • [5] Sentinel lymph node mapping with patent blue dye in patients with breast cancer: a retrospective single institution study
    Olivier, Fabrice
    Courtois, Audrey
    Jossa, Veronique
    Bruck, Gaelle
    Aouachria, Samy
    Coibion, Michel
    Jerusalem, Guy
    GLAND SURGERY, 2021, 10 (09) : 2500 - 2507
  • [6] Sentinel lymph node identification by blue dye in patients with breast carcinoma
    Bakhtiar, Nighat
    Jaleel, Farhat
    Moosa, Foad Ali
    Qureshi, Naeem Akhtar
    Jawaid, Masood
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2016, 32 (02) : 448 - 451
  • [7] Methylene Blue Dye, an Accurate Dye for Sentinel Lymph Node Identification in Early Breast Cancer
    Mathelin, Carole
    Croce, Sabrina
    Brasse, David
    Gairard, Beatrice
    Gharbi, Mouslim
    Andriamisandratsoa, Norosoa
    Bekaert, Virgile
    Francis, Ziad
    Guyonnet, Jean-Louis
    Huss, Daniel
    Salvador, Samuel
    Schaeffer, Roland
    Grucker, Daniel
    Marin, Cristi
    Bellocq, Jean-Pierre
    ANTICANCER RESEARCH, 2009, 29 (10) : 4119 - 4125
  • [8] Methylene blue dye versus combined dye-radioactive tracer technique for sentinel lymph node localisation in early breast cancer
    Varghese, P.
    Mostafa, A.
    Abdel-Rahman, A. T.
    Akberali, S.
    Gattuso, J.
    Canizales, A.
    Wells, C. A.
    Carpenter, R.
    EJSO, 2007, 33 (02): : 147 - 152
  • [9] Sentinel lymph node detection by intranipple injection of patent blue dye in breast cancer: a preliminary report of a feasibility study
    Zervoudis, S.
    Iatrakis, G.
    Paschopoulos, M.
    Dousias, V.
    Geahchan, N.
    Stefos, T.
    Pechlivani, F.
    Navrozoglou, I.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2012, 33 (03) : 304 - 305
  • [10] Can methylene blue dye be used as an alternative to patent blue dye to find the sentinel lymph node in breast cancer surgery?
    Fattahi, Asieh Sadat
    Tavassoli, Alireza
    Rohbakhshfar, Omid
    Sadeghi, Ramin
    Abdollahi, Abbas
    Forghani, Mohammad Naser
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2014, 19 (10): : 918 - 922